SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (941)5/26/1999 4:20:00 PM
From: LLCF  Read Replies (1) of 998
 
Here's a Bloomberg "blurb":

"CEPH shares rose as much as 21% amid optimism about the outlook for sales of it's new drug for sleeping disorder narcolepsy"

"The shares soared amid hopes for success of Provigil, which CEPH introduced in Feb. That product has given new life to the company. Provilgil prescriptions have grown by a better-than-expected compounded weekly growth rate of 21% since launch. BBRS analyst Jay Silverman said in a note to investors. It will likely have 1999 sales of $14million and 2002 sles of 75million, Silverman said."

DAK
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News